Artara Therapeutics Inc (TARA) Stock Price, Quote & News

Company Profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving pare...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 844 0337

Website: www.protaratx.com

Address:

345 Park Avenue South, 3rd Floor, New York, United States

_Moony4x Feb. 25 at 7:16 PM

$ASM $TARA $BRZE $VIAV ++

1 · Reply

Chetmmd Feb. 25 at 4:58 PM

$TARA not only good results from trial but company people very bullish and confident of results. Took this opportunity to add to my position

0 · Reply

RoadToAHouse Feb. 25 at 2:08 PM

$TARA

0 · Reply

RL0102 Feb. 25 at 9:45 AM

$TARA Should we expect any major news in friday's ASCO GU presentation? Anything that will be said that wasn't shared during yesterday's call? I wonder if this has an opportunity to shift the stock's current direction or not... Really shocked by yesterday's movements. Looking at Level II this was also widely driven by Goldman Sachs playing the retail fear game and driving prices down

0 · Reply

pablo4 Feb. 25 at 4:02 AM

$TARA let me say I think Baker Brothers sold out ...not positive.

1 · Reply

pablo4 Feb. 25 at 3:54 AM

$TARA I'm guessing Bakers Brothers kept hitting the bid, thereby driving the price lower as is typical when a fund unloads a position. It is likely it still had a profit in its shares and may have needed the funds to rebalance its portfolio....whether unhappy with the reported results by TARA or any of a host of reasons. But I hope their action translates into a what was a good buying opportunity as happens when a fund just sells a good company at any price for whatever purpose they have for needing the money. JMO

0 · Reply

pablo4 Feb. 25 at 3:42 AM

$TARA https://share.google/aimode/FAhV9x9AUKiFnnyHN

1 · Reply

pablo4 Feb. 25 at 3:28 AM

$TARA Bakers Brothers Life Sciences caused the price drop today, IMO. It filed SEC 144s tonight showing it sold out of its TARA position today.

1 · Reply

Rolo2024 Feb. 24 at 10:57 PM

$TARA Well we finally bottomed out at $5.42 know we will slowly regain some ground upward. By the end of the week $6+

2 · Reply

texmade2 Feb. 24 at 10:35 PM

$TARA BULLISH Extreme bearish 1 day money flow, on an strong-extreme pullback is considered bullish.

0 · Reply

Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer Transcript

Feb 23, 2026, 5:05 PM EST - 2 days ago

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Feb 19, 2026, 8:00 AM EST - 7 days ago

Protara Therapeutics to Participate in Upcoming Investor Conferences

Feb 2, 2026, 4:05 PM EST - 23 days ago

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 22, 2026, 8:00 AM EST - 5 weeks ago

Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

Jan 15, 2026, 12:25 AM EST - 6 weeks ago

Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:00 AM EST - 6 weeks ago

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

Jan 7, 2026, 8:00 AM EST - 7 weeks ago

Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 7 weeks ago

Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations

Dec 8, 2025, 4:05 PM EST - 2 months ago

Protara Announces Closing of $75 Million Public Offering

Dec 4, 2025, 10:03 PM EST - 2 months ago

Protara Announces Pricing of $75 Million Public Offering

Dec 4, 2025, 4:15 PM EST - 2 months ago

Protara Announces Proposed Public Offering

Dec 4, 2025, 7:30 AM EST - 3 months ago

Protara Therapeutics: End Of 2025 Proving Eventful Indeed

Dec 3, 2025, 3:43 PM EST - 3 months ago

Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients Transcript

Dec 3, 2025, 8:00 AM EST - 3 months ago

Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

Dec 1, 2025, 4:15 PM EST - 3 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

Nov 19, 2025, 2:53 PM EST - 3 months ago

Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations Transcript

Nov 19, 2025, 8:00 AM EST - 3 months ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Nov 18, 2025, 4:30 PM EST - 3 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

Nov 17, 2025, 8:00 AM EST - 3 months ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology

Nov 10, 2025, 8:00 AM EST - 3 months ago

Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:05 PM EST - 4 months ago

Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace

Aug 11, 2025, 8:00 AM EDT - 7 months ago

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 30, 2025, 8:00 AM EDT - 8 months ago

Protara Therapeutics Announces Addition to the Russell 3000® Index

Jun 2, 2025, 4:04 PM EDT - 9 months ago

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

May 8, 2025, 8:00 AM EDT - 10 months ago

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Apr 26, 2025, 10:00 AM EDT - 10 months ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Apr 23, 2025, 8:00 AM EDT - 11 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Apr 15, 2025, 4:13 PM EDT - 11 months ago

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Apr 10, 2025, 4:05 PM EDT - 11 months ago

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Mar 28, 2025, 5:10 PM EDT - 11 months ago

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Mar 5, 2025, 8:00 AM EST - 1 year ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 26, 2025, 8:00 AM EST - 1 year ago

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Dec 14, 2024, 8:30 AM EST - 1 year ago

Protara Therapeutics: Rising From The Ashes

Dec 11, 2024, 4:05 PM EST - 1 year ago

Protara Announces Closing of $100 Million Public Offering

Dec 10, 2024, 5:00 PM EST - 1 year ago

Protara Therapeutics: Carving New Roads In Bladder Cancer

Dec 10, 2024, 3:55 PM EST - 1 year ago

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Dec 9, 2024, 11:35 PM EST - 1 year ago

Protara Announces Pricing of $100 Million Public Offering

Dec 5, 2024, 10:50 AM EST - 1 year ago

Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

Nov 15, 2024, 5:52 PM EST - 1 year ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Nov 6, 2024, 8:00 AM EST - 1 year ago

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Sep 9, 2024, 8:05 AM EDT - 1 year ago

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Jun 24, 2024, 5:06 PM EDT - 1 year ago

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 21, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

May 2, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

_Moony4x Feb. 25 at 7:16 PM

$ASM $TARA $BRZE $VIAV ++

1 · Reply

Chetmmd Feb. 25 at 4:58 PM

$TARA not only good results from trial but company people very bullish and confident of results. Took this opportunity to add to my position

0 · Reply

RoadToAHouse Feb. 25 at 2:08 PM

$TARA

0 · Reply

RL0102 Feb. 25 at 9:45 AM

0 · Reply

pablo4 Feb. 25 at 4:02 AM

$TARA let me say I think Baker Brothers sold out ...not positive.

1 · Reply

pablo4 Feb. 25 at 3:54 AM

0 · Reply

pablo4 Feb. 25 at 3:42 AM

$TARA https://share.google/aimode/FAhV9x9AUKiFnnyHN

1 · Reply

pablo4 Feb. 25 at 3:28 AM

$TARA Bakers Brothers Life Sciences caused the price drop today, IMO. It filed SEC 144s tonight showing it sold out of its TARA position today.

1 · Reply

Rolo2024 Feb. 24 at 10:57 PM

$TARA Well we finally bottomed out at $5.42 know we will slowly regain some ground upward. By the end of the week $6+

2 · Reply

texmade2 Feb. 24 at 10:35 PM

$TARA BULLISH Extreme bearish 1 day money flow, on an strong-extreme pullback is considered bullish.

0 · Reply

Bazzzigar Feb. 24 at 10:10 PM

$TARA join with NEO

1 · Reply

ThatTrendingTrader Feb. 24 at 9:39 PM

$TARA

0 · Reply

Rolo2024 Feb. 24 at 8:55 PM

$TARA We will back to $6 by Friday. Then back towards $7+ March 3rd.

0 · Reply

longterminvs Feb. 24 at 8:53 PM

$TARA The reason this is down so much is executions. The data was just slightly less than great but has potential with those not CR'd at 12 months yet. The big issue here is the enrollment. They've got 35 patients out of 100. It's taken nearly 2 years to get 35 patients. At this speed, it's 4 more years for full enrollment. There last raise was to accelerate enrollment but that hasn't happened. Even on todays call the CEO said, "we've been at this a long time".....35 patients out of 100 needed, WTF. If you can't enroll patients are you going to get Dr's to use the drug. I've seen experts state before if enrollment is so slow is the drug that good. Really odd that it's going so slow. Other trials in names I own and owned had a slow start, then they came out with some good data and it took six plus months to get 30 patients then after the data they get to 120 fast because of the results. Not sure why it's not the case here. Can't approve a drug not populated. Why own when it's so far out

1 · Reply

pablo4 Feb. 24 at 8:33 PM

$TARA AI's conclusions: Based on recent 2026 data, there were no significant negative results for TARA-002 in BCG-unresponsive NMIBC; in fact, the interim results are positive. TARA-002 demonstrated a 68% complete response rate at six months in the BCG-unresponsive cohort of the ADVANCED-2 trial. It showed a favorable safety profile with no Grade 3 or greater treatment-related adverse events. Key Findings for TARA-002 in BCG-Unresponsive NMIBC: High Efficacy: The ADVANCED-2 trial showed a 68% complete response (CR) rate at 6 months in BCG-unresponsive patients with carcinoma in situ (CIS). Positive Interim Data: The 12-month data showed promising durability for the treatment. Safety Profile: Adverse events were generally mild (Grade 1), including dysuria and bladder spasms, with no treatment-related discontinuations. Yet, we are being mutilated!! Again...sounds like a contrarian screaming buy to me. JMO

2 · Reply

UgoGreg Feb. 24 at 7:33 PM

$TARA https://youtu.be/ygBN8MilTyc

0 · Reply

Ramanda87 Feb. 24 at 7:17 PM

$TARA I was on the call this morning and read all the recent news… this isn’t negative so why are we down so much???

1 · Reply

Rolo2024 Feb. 24 at 6:42 PM

$TARA We are currently experiencing dead calm! Just a reminder again 2 fireside chats coming up.

0 · Reply

pablo4 Feb. 24 at 6:37 PM

$TARA after reloading trading shares on TARA today, this is where I want to be and have tried for years to get here. I'm out of the market for all practical purposes to where I don't need to fret what the market does tomorrow or next week or next year. The money I still have in the market is in 3 stocks that each have cash, have little to no downside from where they now trade, IMO, but each have tremendous upside. Each is derisked in its space and doesn't require close monitoring. These are TARA, VNDA and PEW. JMO, adios for now.

0 · Reply

RoadToAHouse Feb. 24 at 6:11 PM

$TARA

0 · Reply

RoadToAHouse Feb. 24 at 6:11 PM

$TARA

0 · Reply

RoadToAHouse Feb. 24 at 6:11 PM

$TARA

0 · Reply

Market Cap	282.42M
Revenue (ttm)	0.00
Net Income (ttm)	-44.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,899,700
Avg Vol	1,057,990
Day's Range	N/A - N/A
Shares Out	51.63M
Stochastic %K	30%
Beta	1.38
Analysts	Strong Sell
Price Target	$25.50